Immuneoprofiler™

Guiding the selection of presented and immunogenic neoantigens.

The Immuneoprofiler™ Provides an Holistic Approach to Antigen Presentation Prediction

The Immuneoprofiler™ Provides an Holistic Approach to Antigen Presentation Prediction

OncoImmunity offers software solutions powered by a machine-learning engine, known as the Immuneoprofiler™, that predicts from next generation sequencing data true neoantigens for personalized cancer immunotherapy and cancer immunotherapy biomarkers.

The Immuneoprofiler™ takes a holistic approach to the antigen presentation prediction challenge, by integrating patent pending modules of HLA binding, processing and antigen presentation in an integrated system. Each module significantly outperforms competing approaches.

The key differentiator of the Immuneoprofiler™, is the accurate prediction of antigens that are naturally processed and presented to the tumor cell surface. This unique approach has been validated against clinically relevant neoantigens, increasing the probaility of clinical success for our biopharma partners.

A Unique Approach to Guide the Selection of Clinically Relevant Neoantigens

The Immuneoprofiler™ predicts HLA bound peptides presented on the tumor cell surface through an integrated machine learning algorithm trained on vast amounts of mass spectrometry, binding affinity and other data. The ranked prioritized list empowers and guides the selection of peptides that are both tumor specific and immunogenic.

A Unique Approach to Guide the Selection of Clinically Relevant Neoantigens
Improved Hit Rate for Cell Surface Presentation

Improved Hit Rate for Cell Surface Presentation

The integrated machine learning approach of the Immuneoprofiler™ results in a greatly improved hit rate for the precise design of truly personalized cancer vaccines. Conventional pipelines that include HLA-binding and high expression cutoff typically capture 2 out of 10 possible true hits among over ten thousand possible candidates. However, the holistic machine learning approach performed by the Immuneoprofiler™, in its present form, captures 8 out of 10 possible true hits among the thousand possible candidates.

Improves Your Chance of Clinical Success

The Immuneoprofiler™ significantly outperforms competing prediction tools on clinically validated data. Here, aggregated data from 7 clinical studies that identified validated neoantigens are studied. Interestingly candidates were initially selected because they are predicted binders by the NetMHC family of tools. All positives have been shown to kill autologous tumors or be naturally processed in transfected target cells. Data set includes 725 9mer & 10mer mutated peptides, and contains 23 positives. No expression data was provided in these studies so presentation predictions were based exclusively on inputted binding & processing predictions. The Immuneoprofiler™ is an HLA-agnostic tool and can make predictions for any neoantigen HLA combination.

Improves Your Chance of Clinical Success
Please enable your browser to accept cookies and refresh this page to enjoy the best experience from this website and to dismiss this message.
In order to provide you with the best online experience this website uses cookies. By using our website, you agree to our use of cookies.OK